ACE-031 (1mg)

What is ACE-031?

ACE-031 (also known as ramatercept) is a recombinant fusion protein made of the extracellular part of the human activin receptor type IIB joined to the Fc region of human IgG1. It acts as a decoy receptor that binds myostatin and related proteins of the TGF-beta family, which normally limit muscle growth. It is a protein, much larger than a typical short peptide.

ACE-031 was developed by Acceleron Pharma and Shire and tested in boys with Duchenne muscular dystrophy. That trial was stopped early over safety findings, including nosebleeds, gum bleeding and small dilated blood vessels, and development was ended (Campbell et al., Muscle & Nerve, 2017).

ACE-031 product specifications

• Compound: ACE-031 (ramatercept, ActRIIB-IgG1 Fc fusion protein)
• Type: recombinant fusion protein
• Vial size: 1mg

Regulatory status

ACE-031 is not an approved medicine in the US, UK, EU or Canada, and its clinical development was discontinued. It is on the World Anti-Doping Agency (WADA) Prohibited List. This product is sold for laboratory research use only.

Related research compounds

• Follistatin-344 is a natural binding protein that also targets myostatin and activin.

Handling and research-use notice

Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.